Feedback / Questions
onilcamotide (RV001) - RhoVac
https://www.prnewswire.com/news-releases/rhovacs-phase-iib-study-in-prostate-cancer--bravac-failed-to-meet-its-primary-endpoint-301557156.html
May 29, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next